
mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting Data from 2 major phase 3 trials have demonstrated that progression to clinically definite multiple sclerosis (MS) can be prevented or delayed with early rather than delayed therapy. Two regimens of subcutaneous interferon beta-1a (IFNb) were evaluated in patients who…
Read more »
Early therapy delays progression to clinically definite multiple sclerosis
mdCurrent Conference Report: 64th American Academy of Neurology Annual Meeting Data from 2 major phase 3 trials have demonstrated that progression to clinically definite multiple sclerosis (MS) can be prevented or delayed with early rather than delayed therapy. Two regimens of subcutaneous interferon beta-1a (IFNb) were evaluated in patients who…
Read more »